R C Skoda
Overview
Explore the profile of R C Skoda including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
1190
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Skoda R, Tsai S, Orkin S, Leder P
J Exp Med
. 1995 May;
181(5):1603-13.
PMID: 7722440
To study oncogenesis in the erythroid lineage, we have generated transgenic mice carrying the human c-MYC proto-oncogene under the control of mouse GATA-1 regulatory sequences. Six transgenic lines expressed the...
22.
Shen M, Skoda R, Cardiff R, Leder P, Ornitz D
EMBO J
. 1994 Mar;
13(6):1375-85.
PMID: 8137821
Leukemia inhibitory factor (LIF) is a cytokine involved in embryonic and hematopoietic development. To investigate the effects of LIF on the lymphoid system, we generated a line of transgenic mice...
23.
Skoda R, Seldin D, Chiang M, Peichel C, Vogt T, Leder P
EMBO J
. 1993 Jul;
12(7):2645-53.
PMID: 8334987
The murine myeloproliferative leukemia virus has previously been shown to contain a fragment of the coding region of the c-mpl gene, a member of the cytokine receptor superfamily. We have...
24.
Meyer U, Skoda R, Zanger U
Pharmacol Ther
. 1990 Jan;
46(2):297-308.
PMID: 2181495
The genetic polymorphism of debrisoquine/sparteine metabolism is one of the best studied examples of a genetic variability in drug response. 5-10% of individuals in Caucasian populations are 'poor metabolizers' of...
25.
Meyer U, Zanger U, Skoda R, Grant D, Blum M
Prog Liver Dis
. 1990 Jan;
9:307-23.
PMID: 2156298
No abstract available.
26.
Kimura S, Umeno M, Skoda R, Meyer U, Gonzalez F
Am J Hum Genet
. 1989 Dec;
45(6):889-904.
PMID: 2574001
The debrisoquine-4-hydroxylase polymorphism is a genetic variation in oxidative drug metabolism characterized by two phenotypes, the extensive metabolizer (EM) and poor metabolizer (PM). Of the Caucasian populations of Europe and...
27.
Skoda R, Gonzalez F, Demierre A, Meyer U
Proc Natl Acad Sci U S A
. 1988 Jul;
85(14):5240-3.
PMID: 2899325
The "debrisoquine polymorphism" is a clinically important genetic defect of drug metabolism affecting 5-10% of individuals in Caucasian populations. It is inherited as an autosomal recessive trait. A full-length cDNA...
28.
Gonzalez F, Skoda R, Kimura S, Umeno M, Zanger U, Nebert D, et al.
Nature
. 1988 Feb;
331(6155):442-6.
PMID: 3123997
In population studies of individuals given the antihypertensive drug debrisoquine, two distinct phenotypes have been described: extensive metabolizers excrete 10-200 times more of the urinary metabolite 4-hydroxydebrisoquine than poor metabolizers....
29.
Skoda R, Demierre A, MCBRIDE O, Gonzalez F, Meyer U
J Biol Chem
. 1988 Jan;
263(3):1549-54.
PMID: 2891713
A lambda gt11 expression library constructed from human liver mRNA was screened with an antibody against human microsomal xenobiotic epoxide hydrolase. The clone pheh32 contains an insert of 1742 base...
30.
Christen P, Jaussi R, Sonderegger P, Gehring H, Graf-Hausner U, Behra R, et al.
Prog Clin Biol Res
. 1984 Jan;
144B:17-25.
PMID: 6718400
No abstract available.